Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy.

Jeffrey G Gross, Adam R Glassman, Margaret J Klein, Lee M Jampol, Frederick L Ferris, Neil M Bressler, Roy W Beck

Journal: JAMA ophthalmology 2018;135(6):672-673

PMID: 28492921

Free Full Text on PubMed Central View on PubMed

Abstract

This Research Letter compares treatment with intraviterous ranibizumab with undergoing panretinal photocoagulation for managing proliferative diabetic retinopathy.

Address: Carolina Retina Center, PA Columbia, South Carolina.; Jaeb Center for Health Research, Tampa, Florida.; Feinberg School of Medicine, Northwestern University, Chicago, Illinois.; National Eye Institute, National Institutes of Health, Bethesda, Maryland.; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.

DOI: 10.1001/jamaophthalmol.2017.0969

Link outs

Free resources

Full Text Sources:

Medical:

Other Literature Sources:

https://scite.ai/reports/28492921

Subscription / membership required

Full Text Sources:

MeSH Terms: Angiogenesis Inhibitors, Clinical Trials Data Monitoring Committees, Diabetic Retinopathy, Humans, Information Dissemination, Intravitreal Injections, Laser Coagulation, Patient Safety, Randomized Controlled Trials as Topic, Ranibizumab, Retinal Neovascularization, Vascular Endothelial Growth Factor A, Visual Acuity